AssetMark Inc
ANIK icon

AssetMark Inc’s Anika Therapeutics ANIK Stock Holding History

AssetMark Inc’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$74 – 2593
2024
Q3 		$74 Buy
+3
New +$78 ﹤0.01% 2216
2022
Q1 		– Sell
-72
Closed -$3K – 1541
2021
Q4 		$3K Buy
72
+1
+1% +$40 ﹤0.01% 1305
2021
Q3 		$3K Hold
71
– – ﹤0.01% 1206
2021
Q2 		$3K Buy
71
+1
+1% +$43 ﹤0.01% 1143
2021
Q1 		$3K Buy
70
+6
+9% +$228 ﹤0.01% 1086
2020
Q4 		$3K Sell
64
-7,013
-99% -$266K ﹤0.01% 1097
2020
Q3 		$250K Buy
7,077
+2,372
+50% +$85.7K ﹤0.01% 490
2020
Q2 		$178K Buy
4,705
+2,382
+103% +$78.5K ﹤0.01% 509
2020
Q1 		$67K Buy
2,323
+2,275
+4,740% +$92K ﹤0.01% 631
2019
Q4 		$2K Sell
48
-2
-4% -$116 ﹤0.01% 1215
2019
Q3 		$3K Buy
+50
New +$2.57K ﹤0.01% 1098
2018
Q1 		– Sell
-5
Closed – – 1425
2017
Q4 		$0 Buy
+5
New +$277 ﹤0.01% 1861
2017
Q1 		– Sell
-8
Closed – – 1267
2016
Q4 		$0 Buy
+8
New +$370 ﹤0.01% 1242

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

AssetMark Inc's ANIK Position: Q4 2024 in Review

AssetMark Inc sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 3 shares — an estimated $74 sold.

AssetMark Inc first reported a position in ANIK in Q4 2016 and held it in 13 quarters. The position peaked at $250K in Q3 2020. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • AssetMark Inc reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AssetMark Inc sold 3 Anika Therapeutics shares in Q4 2024, an estimated $74.
  • AssetMark Inc first reported a position in Anika Therapeutics in Q4 2016 and held it in 13 quarters.
  • AssetMark Inc's Anika Therapeutics position peaked at $250K in Q3 2020.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on AssetMark Inc's 13F filing for Q4 2024, filed 6 Feb 2025.